Archive
Proactive news headlines: Open Orphan, Bidstack Group, AFC Energy...
A glance at some of the day's highlights from the Proactive Investors newswire
Company
Oxford Cannabinoid Technologies Holdings PLC
LON:OCTP
Oxford Cannabinoid Technologies Holdings PLC is a well-established, innovative and growing pharmaceutical company developing a portfolio of next generation prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the multi-billion dollar pain market.
54 stories · page 3 of 3
Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech
Stemtech will provide early-stage R&D data support
Oxford Cannabinoid chairman steps down over overdraft facility
Neil Mahapatra will stand down on 11 February 2022
Archive
Proactive News round-up: Oxford Cannabinoid Technologies, MGC Pharmaceuticals Ltd, Westmount, Challenger Energy …
A selection of the stories appearing today on the Proactive website
Oxford Cannabinoid considering ramifications of chairman's overdraft facility
Oxford Cannabinoid understands that Brown Shipley is unable to exercise its security over the pledged shares until July 2022, by which time KCP hopes to have removed the pledged shares from the legal charge
Oxford Cannabinoid Technologies sees good progress across all research programmes
"We believe that our management team, pipeline of drug candidates and network of partners, combined with the significant growth opportunity puts us on a strong footing," said chief executive Dr John Lucas.
Oxford Cannabinoid Technologies targets chronic pain condition with latest formulation
It will use a combination of unnamed phytocannabinoids to treat trigeminal neuralgia, which produces an “excruciating, stabbing, electric shock-like pain”
Archive
Proactive news headlines: Oxford Cannabinoid Technologies, Semper Fortis Esports, Plant Health Care, S&U...
A glance at some of the day's highlights from the Proactive Newswire
Oxford Cannabinoid Technologies hails Canopy Growth licensing deal
"Acquiring an exclusive licence to Canopy Growth's pharmaceutical cannabinoid derivative library is a significant achievement for the group and speaks volumes about our international reputation within our market,” said CEO, Dr John Lucas
Oxford Cannabinoid Technologies on track with plans
OTCP has applied for its shares to be listed on the US OTC QB market.
Oxford Cannabinoid Technologies hails progress following May IPO
The developer of cannabinoid-based prescription medicines said following the listing it had secured two commercial agreements which will “contribute significantly” to the development of its lead compound OCT461201
Oxford Cannabinoid aims to quicken pain treatment development with new partnership
The drug candidate will enter Evotec’s INDiGO programme, an integrated drug development process for accelerating early drug candidates to clinical trial stage, which has an anticipated duration of approximately 12 months
London’s listed cannabis sector doubles in size in first half of 2021
Another handful of new arrivals are due in the next few weeks
Shares in UK cannabis pain medicine developer spike on first day's dealings
The group had an initial valuation of just over £48mln at the issue price of 5p